Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007367 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT04007367 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 53 participants.
The verdict
NCT04007367, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG SAGE-217
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-08-06 |
| Est. Completion | 2020-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04007367
The ClinicalTrials.gov registry entry for NCT04007367 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04007367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04007367 about?
NCT04007367 is a clinical study titled "A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder". This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
What is the current status of trial NCT04007367?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2019-08-06. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT04007367?
The interventions under investigation include: Placebo (DRUG), SAGE-217 (DRUG).
Who is sponsoring clinical trial NCT04007367?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.